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Background: The biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe ([18F] FACT)
was investigated in humans.
Methods: Six healthy subjects (three males and three females) were enrolled in this study. An average of 160.8
MBq of [18F] FACT was intravenously administered, and then a series of whole-body PET scans were performed.
Nineteen male and 20 female source organs, and the remainder of the body, were studied to estimate
time-integrated activity coefficients. The mean absorbed dose in each target organ and the effective dose were
estimated from the time-integrated activity coefficients in the source organs. Biodistribution data from [18F] FACT in
mice were also used to estimate absorbed doses and the effective dose in human subjects; this was compared
with doses of [18F] FACT estimated from human PET data.
Results: The highest mean absorbed doses estimated using human PET data were observed in the gallbladder
(333 ± 251 μGy/MBq), liver (77.5 ± 14.5 μGy/MBq), small intestine (33.6 ± 30.7 μGy/MBq), upper large intestine
(29.8 ± 15.0 μGy/MBq) and lower large intestine (25.2 ± 12.6 μGy/MBq). The average effective dose estimated from
human PET data was 18.6 ± 3.74 μSv/MBq. The highest mean absorbed dose value estimated from the mouse data
was observed in the small intestine (38.5 μGy/MBq), liver (25.5 μGy/MBq) and urinary bladder wall (43.1 μGy/MBq).
The effective dose estimated from the mouse data was 14.8 μSv/MBq for [18F] FACT.
Conclusions: The estimated effective dose from the human PET data indicated that the [18F] FACT PET study was
acceptable for clinical purposes.
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Amyloid beta imaging
Deposits of amyloid β (Aβ) plaque are one of the patho-
logical observations in patients with Alzheimer's disease
(AD); Aβ deposition progresses at an earlier point than
the current clinical diagnostic point for this disease [1].
For earlier diagnosis of AD and the evaluation of treat-
ment efficacy, in vivo amyloid imaging using positron* Correspondence: shidahara@med.tohoku.ac.jp
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in any medium, provided the original work is pemission tomography (PET), which provides quantita-
tion and visualisation of Aβ deposition in the brain, is
useful. Therefore, several Aβ-binding probes dedicated
for PET imaging have been developed [2,3].
Most of these PET Aβ ligands are 11C-labelled com-
pounds (physical half life (T1/2), 20 min), and
18F-labelled
agents are being increasingly investigated owing to their
long half life (T1/2, 109.7 min). The long T1/2 of
18F enables
several PET scans to be carried out from a single synthesis
of labelled agent and also enables its commercial distribu-
tion to any PET facility. On the other hand, the longer the
T1/2 of the radioisotope gets, the greater is the radiationis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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tered dose of radioligand.
Importance of radiation dosimetry
For subjects undergoing PET, internal radiation exposure
is inevitable, and the radiation dose delivered is pro-
portional to the level of radioactivity of the injected
radioligand and the number of injections. In the case of
amyloid imaging, subjects often have multiple PET scans
for diagnostic or therapeutic longitudinal monitoring of
Aβ aggregation in the brain. Therefore, estimation of the
radiation dose exposure from each PET radioligand and
the use of well-balanced PET scan protocols taking into
consideration subject risk and benefit are important.
Estimation of the internal radiation dose requires a time
series measurement of the biodistribution of the injected
radioligand. There are two ways to establish the bio-
distribution of a radioligand in humans: one is to extrapo-
late from data obtained in animal experiments [4] and the
other is to use data from a clinical whole-body PET study
[5]. Data extrapolated from animal experiments have been
used to estimate clinical radiation dose. However, Sakata
et al. reported that in some radioligands, there were con-
siderable differences in organ dose or kinetics between
human and animal experiments and that a whole-body
PET study would be desirable for the initial clinical evalu-
ation of new PET radioligands [6].
Previous biodistribution and dosimetry study for PET
amyloid imaging
Recently, radiation dose exposures from several PET amyl-
oid imaging agents have been reported using clinical
whole-body PET scans. One of the popular amyloid li-
gands, Pittsburgh compound B ([11C]PIB), has been exten-
sively investigated with regard to its kinetics in the human
body, and its effective radiation dose was found to be 4.74
μSv/MBq on average [7]. For 18F-labelled PET amyloid
radioligands, effective doses in humans have been reported
as follows: 18F-AV-45, 13 and 19.3 μSv/MBq [8,9];
18F-GE067, 33.8 μSv/MBq [10]; and 18F-BAY94-9172, 14.7
μSv/MBq [11].
Aim of the present study
Fluorinated amyloid imaging compound ([18F]FACT) is
an 18F-labelled amyloid imaging agent developed at
Tohoku University [12]. Kudo and colleagues at this uni-
versity have previously developed a 11C amyloid imaging
agent named [11C]BF-227 [3]. [18F]FACT is derived from
[11C]BF-227 by reducing its lipophilicity in order to re-
duce the nonspecific binding in the brain; AD patients
showed significantly higher uptake of [18F]FACT in the
neocortex region relative to controls [12]. However, the
biodistribution of [18F]FACT in humans has not yet been
investigated.In the present study, the radiation dosimetry and
biodistribution of [18F]FACT was investigated in healthy
elderly subjects who are the target group for PET amyl-
oid imaging. In order to determine the discrepancy in
the estimated radiation dose between human and animal
experiments, biodistribution studies in mice involving
[18F]FACT were also conducted.
Methods
Subjects
PET studies were performed in three healthy male and
in three healthy female volunteers (mean age ± standard
deviation (SD), 76.3 ± 3.2 years). Subject characteristics
are shown in Table 1. Both height and weight varied
over a wide range (146 to 175 cm and 39 to 74 kg, re-
spectively). All subjects were Japanese and were free of
somatic and neuropsychiatric illness, as determined by
clinical history and physical examination; one male sub-
ject (no. 1) had undergone a previous surgical operation
involving gallbladder removal.
This study was approved by the Ethics Committee on
Clinical Investigations of Tohoku University School of
Medicine and was performed in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from all subjects after a complete description
of the study had been made.
Radiochemistry and radioligand purity
Figure 1 shows the chemical structure of 18F-FACT. The
radiochemical purity of the radioligand in the present
clinical study ranged from 97.8% to 98.7% (mean ± SD,
98.33 ± 0.42%). The specific radioactivity ranged from
30.6 to 347.7 GBq/μmol at the time of injection (mean ±
SD, 139.9 ± 116.2 GBq/μmol).
PET study
All whole-body PET studies were performed using a
SET-2400W scanner (Shimadzu Inc., Kyoto, Japan) in
two-dimensional (2D) mode [13]. The PET scanner ac-
quired 63 image slices at a centre-to-centre interval of
3.125 mm and had a spatial resolution of 3.9 mm full
width at half maximum (FWHM) and a Z-axis reso-
lution of 6.5 mm FWHM at centre field of view [13].
An overview of scan protocols is shown in Figure 2.
Four emission scans and two transmission scans (before
administration and intermediate emission scans) using
a 68Ge/68Ga source were performed, with the exception
of subject no. 1 who had three emission scans. In the
present series of PET studies and in other research pro-
jects, a 15-min PET brain scan using three-dimensional
(3D) mode was performed after the first emission scan.
At 2 min after intravenous administration of 142 to 180
MBq [18F]FACT (mean ± SD, 160.8 ± 14.8 MBq; injec-
tion mass, 0.77 ± 0.66 ng), a series of whole-body PET
Table 1 Information regarding the human subjects
Sex Age (years) Height (m) Weight (kg) BMI (kg/m2) History
Subject number
1 M 77 1.59 61.2 24.2 Surgical removal of gallbladder
2 M 78 1.62 65 24.8 -
3 M 77 1.75 74 24.2 -
4 F 70 1.46 39 18.3 -
5 F 77 1.56 60.2 26.1 -
6 F 79 1.55 56 23.3 -
Mean ± 1 SD 76.3 ± 3.2 1.58 ± 0.75 59.2 ± 11.6 23.5 ± 2.7
Shidahara et al. EJNMMI Research 2013, 3:32 Page 3 of 10
http://www.ejnmmires.com/content/3/1/32scans were performed. The schedule for the first and
second transmission scans and the first, second, third
and fourth emission scans was as follows: 6 positions ×
4 min (24 min), 6 positions × 4 min (24 min), 6 posi-
tions × 3 min (18 min), 6 positions × 3 min (18 min),
6 positions × 3 min (18 min), and 6 positions × 4 min
(24 min), respectively. The starting time of the second
emission scan was different for each subject and was on
average 55 min after the start of injection with a 5-min
SD. The time gap between bed positions was 5 s. All
emission data were reconstructed using OS-EM with it-
eration 16 and subset 2 after attenuation correction.
Scatter correction was not performed because of the use
of 2D mode data acquisition. The cross calibration factor
of the scanner (Bq per ml/cps per voxel) was determined
once per week using a cylindrical water phantom (25-cm
length and 20-cm inner diameter) filled with 18F solu-
tions and by measuring the sample activity of the 18F
solutions at the well counter (BSS-3: Shimadzu Co., Ltd.,
Kyoto, Japan) [14].
Urination was controlled before, after and during the
series of PET studies. In particular, during (15 min after
the end of the first emission scan) and after the PET
scans, subjects were asked to void. The volume and
radioactivity levels of their urine samples were measured
using a calibrated well counter.
MRI study
All subjects underwent T1-weighted magnetic resonance
imaging (MRI) scans using a Signa 1.5-T machine (Gen-
eral Electric Inc., Milwaukee, WI, USA) within a week of
the PET scans. For each position (brain, chest, abdomenFigure 1 Chemical structure of 18F-FACT.and epigastric region), individual T1-weighted scans with
a voxel size of 1.875 × 1.875 × 6.000 mm (TR = 460 ms,
TE = 14 ms, image matrix = 256 × 256 × 40) were
obtained with subjects holding their breath.
Dosimetry
The Medical Internal Radiation Dose committee of the
Society of Nuclear Medicine developed the algorithm to
calculate absorbed dose D (the energy deposited per unit
mass of medium (Gy)) in organs. The basic idea is that
radiation energy from the radioisotope in the source
organ is absorbed in the target organs, and the algorithm
requires the net accumulated radioactivity in source or-
gans as an input [15]. A PET scan contributes to quanti-
tative knowledge on the whole-body distribution of
radioisotope. In the present study, the accumulated ac-
tivity in source organs was derived from PET measure-
ments and the organ volumes of the reference male or
female. The mean absorbed dose to the kth target organ
is defined as follows:
D rkð Þ ¼ ∑
h
~AhS rk←rhð Þ ¼ ∑
h




where S(rk ← rh) is the absorbed dose in the kth target
organ per unit of accumulated activity in the hth source
organ, called the S value. ~Ah is the number of disintegra-
tions in the hth source organ, A0 is the injected dose,
and τh is the time-integrated activity coefficient in the
hth source organ (equal to the number of disintegrations
per unit activity administered). The effective dose E (Sv),
as defined by the International Commission on Radio-





where Di is the absorbed dose of the ith target organ, wi
is the weighting risk factor in the ith target organ, and Q
is the quality factor (Q = 1 for β- and γ-rays).
Figure 2 Overview of PET scan protocols. Four emission scans and two transmission scans (before and intermediate emission scans) with a
68Ge/68Ga source were performed. In particular, the second transmission scan was performed using a post-injection transmission scan.
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The number of source organs used for region-of-interest
(ROI) drawing was 19 for male and 20 for female subjects.
A detailed list of source organs is shown in Table 2. Two
nuclear medicine physicians manually drew the ROIs
using PMOD version 3.1 (PMOD Technologies, Zurich,
Switzerland). All individual PET images and MRI imagesTable 2 [18F]FACT time-integrated activity coefficients in the
Organ Hu
Mean ± 1 SD Subject 1 Subj
Adrenal gland 5.38E−04 ± 2.98E−04 9.40E−04 8.40
Brain 4.20E−02 ± 8.44E−03 5.41E−02 3.68
Breast 8.40E−03 ± 4.37E−03 1.14E−03 8.25
Gallbladder contenta 2.22E−01 ± 1.05E−01 - 1.49
Lower large intestine content 2.12E−02 ± 2.03E−02 5.91E−02 1.06
Small intestine content 8.78E−02 ± 1.08E−01 7.40E−02 3.74
Stomach content 6.71E−03 ± 2.28E−03 5.22E−03 6.23
Upper large intestine content 2.55E−02 ± 1.89E−02 1.48E−02 4.88
Heart content 1.12.E−02 ± 1.51E−03 1.24E−02 1.13
Heart wall 7.50E−03 ± 1.84E−03 4.63E−03 1.00
Kidney 1.34E−02 ± 3.27E−03 1.32E−02 1.16
Liver 4.92E−01 ± 1.05E−01 6.28E−01 5.85
Lung 3.55E−02 ± 1.16E−02 3.78E−02 5.31
Muscle 4.66E−01 ± 3.73E−01 9.43E−01 5.47
Ovaryb 5.53E−04 ± 3.79E−05 -
Pancreas 4.13E−03 ± 9.75E−04 6.10E−03 3.62
Red marrow 3.98E−02 ± 4.33E−03 4.02E−02 3.83
Spleen 5.41E−03 ± 1.74E−03 8.64E−03 4.88
Testisc 5.77E−04 ± 4.67E−04 7.00E−04 6.10
Thyroid 3.53E−04 ± 1.55E−04 6.30E−04 3.70
Urinary bladder contents 2.26E−02 ± 8.36E−03 1.70E−02 2.69
Uterus/uterine wallb 4.46E−03 ± 1.90E−03 -
Remainder of the body 1.17 ± 3.63E−01 7.24E−01 1.
Averaged time-integrated activity coefficient (MBq-h/MBq) for the source organs (n
subjects of [18F]FACT and mice of [18F]FACT. aAveraged value among five subjects e
female subjects (n = 3). cAverage time-integrated activity coefficient among male suwere co-registered to the first individual PET images using
a rigid matching module of the same PMOD with a dis-
similarity function of normalised mutual information (for
MRI-to-PET cases) and the sum of the absolute difference
(for PET-to-PET cases) algorithms.
For visceral organs with extremely high uptake (liver




ect 2 Subject 3 Subject 4 Subject 5 Subject 6
E−04 5.20E−04 3.70E−04 4.00E−04 1.60E−04 -
E−02 3.53E−02 4.87E−02 4.42E−02 3.26E−02 6.99E−03
E−03 5.59E−03 1.16E−02 1.19E−02 1.19E−02 -
E−01 2.27E−01 3.88E−01 1.16E−01 2.31E−01 -
E−02 4.80E−03 2.27E−02 2.40E−02 5.96E−03 -
E−02 3.34E−02 3.06E−01 3.36E−02 4.25E−02 1.22E−01
E−03 9.29E−03 9.84E−03 4.78E−03 4.87E−03 -
E−02 1.01E−02 4.99E−02 2.04E−02 8.85E−03 -
E−02 1.02E−02 1.30E−02 1.15E−02 8.83E−03 3.95E−03
E−02 8.84E−03 6.75E−03 7.28E−03 7.49E−03 2.39E−03
E−02 1.53E−02 1.89E−02 9.59E−03 1.20E−02 9.34E−03
E−01 4.34E−01 5.15E−01 3.42E−01 4.49E−01 1.69E−01
E−02 4.36E−02 2.46E−02 2.33E−02 3.08E−02 1.17E−02
E−01 7.97E−01 5.40E−02 4.12E−01 4.34E−02 1.57E−01
- - 5.70E−04 5.10E−04 5.80E−04 -
E−03 3.93E−03 3.81E−03 3.55E−03 3.76E−03 -
E−02 3.79E−02 4.59E−02 4.29E−02 3.34E−02 1.61E−02
E−03 3.83E−03 6.01E−03 4.77E−03 4.30E−03 1.28E−03
E−05 9.70E−04 - - - -
E−04 3.60E−04 2.40E−04 1.80E−04 3.40E−04 -
E−02 1.55E−02 3.63E−02 2.49E−02 1.51E−02 6.56E−02
- - 6.42E−03 2.63E−03 4.33E−03 -
06 9.48E−01 1.08 1.51 1.69 2.08
= 6) from the whole-body PET data (n = 6) from experiments involving human
xcluding subject no. 1. bAverage time-integrated activity coefficient among
bjects (n = 3).
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maximum counts (first emission for the liver and third
or fourth emission for the gallbladder). Then the ROI
was applied to the other emission images with minor ad-
justment of its location or shape. For the intestines, if
specific high uptake was observed, individual ROIs were
defined on each time frame of the PET images with
about a 10% threshold. If there was no specific high up-
take in the intestines, and uptake could be regarded as
uniform, individual ROIs were drawn around the corre-
sponding area.
In order to obtain a typical radioactivity concentration
within organs with less location mismatch between PET
and the co-registered MRI images (brain, breast, heart
wall, heart contents, kidney, liver, lung, muscle, bones,
spleen and thyroid), individual ROIs were drawn on co-
registered MRI images. For other low-uptake organs (ad-
renal gland, stomach contents, pancreas, ovary, uterus
and testis), individual ROIs were drawn on each time
frame of the PET images and referred to the co-
registered MRI images. To avoid a partial volume effect,
the size of the ROI for these MRI available organs was
made slightly smaller than the entire source organ. It
should also be noted that all activities in vertebrae ROIs
was assumed to be in the red marrow in the present
study.Data analysis
Averaged time-activity curves for each organ were
obtained using the ROI values from each subject's PET
images. Because the PET images were decay-corrected at
the start of each scan during the reconstruction proced-
ure, the non-decay-corrected time-activity curves (C(t),
Bq/ml) were re-calculated. During each whole-body
emission scan, the bed position was moved from the foot
to the head (six bed positions in total). However, we
assumed that PET counts at all bed positions were
acquired at the mid-scan time. Then, individual radio-
activity concentration per injected dose A0 (Bq) was ex-
trapolated into the percent injected dose (%ID) of the
reference subject as follows:





 V reference ð3Þ
where V (ml) is the organ volume, and Vreference is V of
the reference subject (we used a 70-kg adult male and
58-kg adult female as the male and female reference
subjects) [16,17]. Even though some organs such as the
intestine may change their volume over time, we used
the reference subjects' organ volumes over the time
period of the calculation of the %ID.The time-integrated activity coefficient τ (Bq-h/Bq) in
Equation 1 was obtained by fitting (%ID(t)) using a
mono-exponential function and integrating from time
zero to infinity. If the time-activity curve did not
converge at the last PET scan (e.g. intestines and gall-
bladder), time-activity curves were fitted using two ex-
ponential functions, and then the area under the curve
after the acquisition of the last image was calculated by
assuming only physical decay of 18F and no additional
biologic clearance to be conservative [10]. The time-
integrated activity coefficient for urinary bladder content
was calculated by applying the dynamic urinary bladder
model [10] to the urine samples with a bladder voiding
interval of 2 h. The decay-corrected cumulative activity
for urine was fitted using the equation A × (1 − exp(−ln
(2) × t / τ)), where τ is the biological decay and A is the
fraction of activity released from the body. The sum of
the time-integrated activity coefficient for the specific
organs was subtracted from the time-integrated activity
coefficient for the total body, which was calculated from
the time integral of the decaying injected radioactivity.
Then the residual of the subtraction was regarded as the
time-integrated activity coefficient in the remainder of
the body. All fitting procedures were undertaken using a
mean fit of R2 of 0.93 ± 0.13.
Finally, the time-integrated activity coefficient τ (Bq-h/Bq)
was used to calculate the absorbed dose, D, in Equation 1
and the effective dose, E, in Equation 2. Both kinetics cal-
culations (fitting and integration) and dose estimation
were performed using OLINDA/EXM software ver-
sion 1.0 (Department of Radiology and Radiological
Sciences Vanderbilt University, Nashville, TN, USA)
[17].Animal experiments
The experimental protocols were reviewed by the Com-
mittee on the Ethics of Animal Experiments at Tohoku
University School of Medicine and performed in accord-
ance with the Guidelines for Animal Experiments issued
by the Tohoku University School of Medicine. Estimated
radiation dose of [18F]FACT in the human subjects cal-
culated from mouse data sets was compared with those
of [18F]FACT from human whole-body PET scans. An
average dose of 1.4 MBq of [18F]FACT was intravenously
injected into ICR mice (age, 6 weeks; average body
weight, 30 g) without anaesthesia. In the [18F]FACT
study, the mice were killed by cervical luxation at 2,
10, 30, 60 and 120 min ([18F]FACT) after administra-
tion (n = 4 at each time point). The masses of the
blood, heart, lung, liver, spleen, small intestine, kidney,
brain and urine samples were measured, and activity
was also measured using a well counter. Thigh bone and
muscle were also sampled. The average uptake of the
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where the bodyweight of the mouse was assumed to be
30 for [18F]FACT.
Finally, in the same manner as in the human PET data
analysis, time-integrated activity coefficients, absorbed
doses and effective doses were calculated using the
OLINDA/EXM software version 1.0. Sampled blood,
thighbone and urine were regarded as heart contents,




Figure 3A is the coronal PET image for a single female
subject (no. 5) and demonstrates the typical bio-
distribution of [18F]FACT in the human body. The
highest accumulations of this radioligand were observed
in the gallbladder, liver, intestine and urinary bladder.
For subject no. 1, [18F]FACT contained in the bile was
excreted from the liver to the duodenum through the
biliary tract (Figure 3B). The biodistribution pattern of
[18F]FACT in human subjects showed a predominant
hepatobiliary excretion, which is similar to what has
been observed for other amyloid ligands, such as [11C]
PIB, [18F]AV-45, [18F]GE067 and [18F]BAY94-9172
[7,8,10,11].Figure 3 Decay-corrected coronal radioactivity distributions. Subject nFigure 4 shows the decay-corrected time-activity curve
of the %ID for typical source organs (brain, liver, spleen,
lung, kidney, heart content, heart wall, muscle, red mar-
row, small intestine contents, gallbladder, upper large in-
testine contents and urinary bladder) from the six
volunteers and the mice experiments. A significant dif-
ference between the %ID from humans and mice was
observed in the brain, liver, spleen, heart contents, red
marrow and urinary bladder, and these differences prop-
agated the different results regarding dose estimation. In
human subjects, 18F uptake in the gallbladder contents
and the intestines (Figure 4J,K,L) indicated larger indi-
vidual variations in radioactivity uptake relative to other
organs (e.g. the kidney as shown in Figure 4E). Radio-
activity uptake in the upper large intestine showed
propagation of both ligand kinetics and inter-subject
variation from the gallbladder (Figure 4K,L). Scheinin
et al. previously reported that inter-subject variation in lig-
and uptake ([11C]PIB) in the gallbladder may be due to the
quality and quantity of post-injection food intake [7]. In
the present study, the subjects drank water during the
interval between the first and second PET scans. This may
have been responsible for the increase in inter-subject
variation regarding the gallbladder. Furthermore, because
the gallbladder uptake in some subjects had declined or
remained at a low level at the final time points, we as-
sumed that there was only physical radioactive decay after
the last PET scans. However, this assumption may have
led to a conservative estimation of the absorbed dose.
Figure 5 presents typical brain PET images obtained
using [18F]FACT at different time points with ano. 5 (A) and subject no. 1 (B) at each PET measurement.
Figure 4 Decay-corrected time-activity curves of %ID. (A) Brain, (B) liver, (C) spleen, (D) lung, (E) kidney, (F) heart content, (G) heart wall, (H)
muscle, (I) red marrow, (J) SI contents, (K) gallbladder, (L) ULI content and (M) urinary bladder for individual human (dashed black line) and
averaged mice extrapolation (n = 4 at each time point, grey line). The solid black line indicates fitted curve using exponential function from all
subjects' data points. The urinary bladder curve indicates accumulated activity excreted at all voiding/sampling moments.
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sion) and 4 min (fourth emission). There was no signifi-
cant retention of [18F]FACT in the brain, and this may
have been because the subject was normal.
Estimated dose of [18F]FACT
The [18F]FACT time-integrated activity coefficients in
the source organs are shown in Table 2, and the
absorbed doses are shown in Table 3. The averaged
time-integrated activity coefficient for the gallbladder, as
shown in Table 2, was calculated among five subjectsFigure 5 Decay-corrected brain PET images of subject no. 3 at differeexcluding subject no. 1; however, in the case of the aver-
aged absorbed and effective doses, subject no. 1 was in-
cluded (Table 3).
High absorbed dose in humans was observed in the
gallbladder (333 ± 251 μGy/MBq), liver (77.5 ± 14.5
μGy/MBq), small intestine (33.6 ± 30.7 μGy/MBq),
upper large intestine (29.8 ± 15.0 μGy/MBq) and lower
large intestine (25.2 ± 12.6 μGy/MBq). In mice, high
absorbed doses were observed in the small intestine
(38.5 μGy/MBq), liver (25.5 μGy/MBq) and urinary blad-
der wall (43.1 μGy/MBq) for [18F]FACT (Table 3).nt time points.
Table 3 Absorbed doses in the source organs
Human Mouse
All subjects (n = 6) Male Female
(n = 3) (n = 3)
Organ
Adrenal gland 1.96E01 ± 2.00 2.03E01 1.90E01 1.35E01
Brain 9.91 ± 1.82 8.95 1.09E01 4.17
Breasts 8.69 ± 2.55 6.68 1.07E01 9.90
Gallbladder wall 3.33E02 ± 2.51E02 2.16E02 4.50E02 1.68E01
Lower large intestine wall 2.52E01 ± 1.26E01 2.41E01 2.63E01 1.57E01
Small intestine 3.36E01 ± 3.07E01 2.07E01 4.64.E01 3.85E01
Stomach wall 1.61E01 ± 3.44 1.35E01 1.87E01 1.39E01
Upper large intestine wall 2.98E01 ± 1.50E01 2.36E01 3.59E01 1.83E01
Heart wall 1.62E01 ± 1.70 1.50E01 1.74E01 8.34
Kidneys 2.01E01 ± 4.30 1.85E01 2.17E01 1.32E01
Liver 7.75E01 ± 1.45E01 7.38E01 8.11E01 2.55E01
Lungs 1.46E01 ± 1.10 1.49E01 1.43E01 7.96
Muscle 1.03E01 ± 1.27 1.07E01 9.90 7.89
Ovary 1.67E01 ± 6.65 1.18E01 2.16E01 1.67E01
Pancreas 2.32E01 ± 3.11 2.17E01 2.47E01 1.45E01
Red marrow 1.31E01 ± 1.70 1.16E01 1.46E01 1.23E01
Osteogenic cells 1.60E01 ± 3.65 1.25E01 1.95E01 1.82E01
Skin 7.30 ± 1.39 5.99 8.60 8.70
Spleen 1.37E01 ± 2.48 1.27E01 1.48E01 7.83
Testis 7.32 ± 2.16 7.32 - 1.15E01
Thymus 1.00E01 ± 1.85 8.37 1.16E01 1.08E01
Thyroid 8.36 ± 1.38 8.86 7.86 1.10E01
Urinary bladder wall 2.23E01 ± 7.33 1.81E01 2.66E01 4.31E01
Uterus 1.67E01 ± 8.13 1.14E01 2.19E01 1.77E01
Total body 1.38E01 ± 1.63 1.22E01 1.53E01 1.22E01
Effective dose (μSv/MBq) 1.86E01 ± 3.74 1.64E01 2.09E01 1.48E01
Averaged absorbed dose estimates (μGy/MBq) for the target organs from the whole-body PET data (n = 6) from experiments involving human subjects of [18F]
FACT and mice of [18F]FACT. Average absorbed dose for male subjects (n = 3).
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study was 18.6 ± 3.74 μSv/MBq. The effective doses of
[18F]FACT estimated from the clinical PET studies
among other 18F-labelled PET amyloid radioligands were
as follows: [18F]AV-45, 13 and 19.3 μSv/MBq [8,9]; [18F]
GE067, 33.8 μSv/MBq [10]; and [18F]BAY94-9172, 14.67
μSv/MBq [11]. For PET analysis of [11C]PIB, Scheinin
et al. normalised the %ID using the ratio of individual
and reference subjects' body weights (Equation 4) [7].
However, in the present study, we did not normalise the %ID
data because there was a small difference between the
effective dose with normalisation (17.6 ± 2.12 μSv/MBq)
and the present effective dose (18.6 ± 3.74 μSv/MBq).
Therefore, we concluded that body weight normalisation
does not influence the effective dose.The effective dose of [18F]FACT from the mouse ex-
periments (14.8 μSv/MBq) was underestimated as
compared with that from the human subject PET studies
(18.6 μSv/MBq) (Table 3). This discrepancy corres-
ponded to 0.76 mSv (2.96 and 3.72 mSv from mice and
humans, respectively) while assuming an injected activity
of 200 MBq as a clinically relevant dose. The underesti-
mation of absorbed dose in the mouse gallbladder (20
times lower) and liver (3 times lower) relative to the
human PET studies may have been responsible for the
underestimation of the effective dose. High absorbed
doses in the liver, gallbladder and small intestine of mice
indicated that the biodistribution pattern of [18F]FACT
in mice includes hepatobiliary excretion, as was observed
in the PET scans involving human subjects. However,
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times lower than the estimate from human subject data
sets because we could not remove the gallbladder of the
mouse. Therefore, to evaluate the effective dose of [18F]
FACT in target organs, a whole-body PET scan of hu-
man subjects may be preferable as compared with the
extrapolation from mouse experiments.
Clinical applicability of [18F]FACT
The present whole-body PET study was performed using
healthy elderly subjects and not patients with AD. Previ-
ously, Koole et al. speculated that if brain uptake of 18F
amyloid ligand increased by a factor of three, this will only
influence estimation of the effective dose within 1%; how-
ever, when the subject had taken medication that changed
the function of the hepatic metabolism, the estimated
effective dose will vary with a larger range [10].
In the present series of PET studies, brain PET scans
using the 3D mode were performed between the first
and the second emission scan. Therefore, the injected
dose for 2D whole-body scans was set to lower level
than usual, and the averaged injected activity of 160.8
MBq corresponded to a radiation dose of 2.99 mSv
per single administration. With regard to the optimal
injected activity that can ensure sufficient image quality
for clinical use, the peak noise-equivalent counts ratio
(NECR) is often used in its determination. It has also
been reported that the peak NECR in 2D mode was not
reached with an acceptable range of injected activity,
whereas in 3D mode, there was a distinct maximum for
the NECR for which the corresponding injected activity
was based on patient height and weight [19]. For the
scanner used in our study, the NECR peak in 3D mode
was reached at 4.44 kBq/ml using an 8,000-ml phantom
[13]. When the subject's height and weight were as-
sumed to be 170 cm and 60 kg, respectively, this as-
sumption corresponded to the optimal injected dose of
about 260 MBq. In a real situation, there exists the effect
of the activity outside the axial FOV, and the optimal
injected dose would be much lower. Injected activity in-
dicates radiation dose; for example, 200 MBq indicates a
radiation dose of 3.72 mSv. ICRP 62 [20] recommended
that the maximum radiation dose that causes a ‘minor to
intermediate’ increase of risk levels while preserving so-
cial benefit levels that are ‘intermediate to moderate’ has
an effective limit of 10 mSv/year [20,21]. Thus, the max-
imum injectable activity is 537.6 MBq [18F]FACT/year,
and this injection dose limit allows two or three PET
scans to be performed. Furthermore, amyloid imaging is
mainly undertaken in elderly patients aged >50 years,
even though for early detection of AD, patients aged <50
years will also have an amyloid PET scan. According to
the guidance on medical exposures in medical and bio-
medical research by the European Commission [22],dose restrictions for patients aged over >50 years are not
as strict as for younger patients. Therefore, considerably
more multiple PET scans may be possible.
Conclusions
The effective dose of the 18F-labelled amyloid imaging agent,
[18F]FACT, was found to be acceptable for clinical study.
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